Journal of Ophthalmology

Clinical Study

Effect of the Duration of Intraretinal or Subretinal Fluid on the Response to Treatment in Undertreated Age-Related Macular Degeneration

Table 5

Characteristics of changing timing of each patterns of change.
 C ⟶ PC ⟶ P in C ⟶ P ⟶ CP ⟶ C in C ⟶ P ⟶ CP ⟶ CP ⟶ C in P ⟶ C ⟶ PC ⟶ P in P ⟶ C ⟶ P
Number (eyes)4771733
Timing of change from the first visit (months)44.63 ± 20.12 (range, 25–44)27.35 ± 21.39 (range, 4–67)42.85 ± 17.96 (range, 23–77)24.41 ± 42.03 (range, 3–48)27.17 ± 10.21 (range, 15–39)58.67 ± 22.11 (range, 28–77)
Accumulated IRF until the change (months)9.0 ± 10.98 (range, 0–24)11.04 ± 5.21 (range, 2–19)21.46 ± 11.38 (range, 3–43)10.04 ± 18.59 (range, 0–24)8.17 ± 7.55 (range, 0–19)19.33 ± 17.06 (range, 0–42)
Accumulated SRF until the change (months)13.0 ± 6.98 (range, 5–22)13.07 ± 11.22 (range, 2–30)20.64 ± 12.44 (range, 2–40)16.55 ± 11.26 (range, 5–41)15.33 ± 6.38 (range, 7–23)26.50 ± 16.68 (range, 5–50)
Number of injections until the change (times)8.25 ± 4.57 (range, 3–14)7.43 ± 4.44 (range, 3–14)10.14 ± 4.36 (range, 5–17)6.71 ± 3.60 (range, 3–18)6.0 ± 2.45 (range, 3–9)9.33 ± 3.40 (range, 6–14)
Injection span (months/number)7.16 ± 4.98 (range, 3–12)3.62 ± 1.43 (range, 1–5)5.63 ± 2.81 (range, 3–11)※3.76 ± 2.69 (range, 1–9)6.12 ± 4.92 (range, 2–13)9.24 ± 2.39 (range, 6–12)※
Aflibercrpt/ranibizmab2/22/5✳4/315/23/0✳2/1
Switching ranibizumab  ⟶ Aflibercept112300
Switching aflibercept  ⟶ Ranibizmab000101
No switching at the point3651332
Previous PDT1/41/70/73/172/30/3
Vertical row shows the each pattern of change and horizontal line show the characteristics of the change timing. , ※ (Mann–Whitney U-test), and ✳ (Fisher’s exact test). Other pairs were not significantly different (Mann–Whitney U test, Wilcoxon signed-rank test, Kruskal–Wallis test, and Cramer’s V test). Note. C ⟶ P in C ⟶ P ⟶ C: whole change pattern is completely effective ⟶ partially effective ⟶ completely effective, and this row shows about effect change completely effective ⟶ partially effective.